Global CAR T-cell Therapy Market Growing at a CAGR of Around 5.6% and Valuation US$ 2.8 Bn over the Forecast Period (2022-2032) | Top Leaders - Novartis AG, Gilead Sciences Inc. - PMR

"Increasing prevalence of cancer and continuous R&D on cell-based therapies are expected to drive demand for CAR T-cell therapy over the decade," says a Persistence Market Research analyst.
CAR T-Cell Therapy Market: Requirement for Treatment of Relapsed Large B-Cell Lymphoma High

According to a recent study by Persistence Market Research, the global CAR T-cell therapy market is anticipated to experience high growth over the coming years. The market is expected to grow from US$ 1.2 Bn in 2020 to over US$ 2.8 Bn by 2031, which reflects a CAGR of around 5.6% for the next ten years.

Request For Free Sample Report of "CAR T-Cell Therapy Market"@ https://www.persistencemarketresearch.com/samples/28264

Key players in the CAR T-cell therapy space are focusing on acquisitions and collaborations with other players of the market to strengthen their position by offering a wide range of products.
For instance, in December 2017, Gilead Science acquired Cell Design Labs Inc., which is a privately held company of biotherapeutics that discovers and develops cell-based therapies. This acquisition benefits Gilead through gaining novel technology platforms that will its boost R&D efforts in cellular therapy.

Also, increasing number of clinical trials in the field of life sciences and CAR T-cells will benefit manufacturers and researchers in developing innovative cancer therapy. With a large extent of studies taking place around CAR T-cell therapy, it is anticipated to enhance product availability in the market over the coming years.

Global Market Analysis Study -

• By product, Yescarta (axicabtagene ciloleucel) holds high share of approximately 59%.
• By indication, relapsed large B-cell lymphoma accounts for approximately 93% market share.
• By end user, cancer treatment centers account for around 92% share in the market.
• By region, North America holds the largest share of 68.1% of the global CAR T-cell therapy market, due to increasing number of life science companies focusing on the development and commercial manufacturing of CAR T-cells in the region.

Buy Full Report Now and Get Up to 20% Discount @ https://www.persistencemarketresearch.com/checkout/28264

Competitors Analysis in CAR T-cell Therapy Industry -

• Many of the chief players in the CAR T-cell therapy market are focusing on product launches and collaborations for global expansion.
• In March 2018, Celgene Corporation completed the acquisition of Juno Therapeutics, Inc. This acquisition helps Celgene advance in cellular immunotherapy by adding novel technology and advanced cellular manufacturing capabilities to its portfolio.
• In August 2017, Gilead Science announced the acquisition of Kite Pharma Inc., an industry leader in the emerging field of cell therapy.
• In March 2021, Kite Pharma gained FDA approval for axicabtagene ciloleucel (axi-cel), a CAR T-cell based therapy.

Want More Insights?

Persistence Market Research brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031.

The market is segmented in detail based on product (Yescarta (axicabtagene ciloleucel), Kymriah (tisagenlecleucel), JCAR017 (lisocabtagene maraleucel), and bb2121) indication (Relapsed Large B-cell Lymphoma, Acute Lymphoblastic Leukemia (ALL), and Multiple Myeloma), and end user (hospitals and cancer treatment centers), across seven major regions of the world.

Request Customization @ https://www.persistencemarketresearch.com/request-customization/28264

Key Questions Answered in This Report.
• What are the Roadblocks for CAR T-Cell Therapy Market Suppliers?
• What are the Key Opportunities for CAR T-Cell Therapy Market Manufacturers?
• How is Focus on Safety Influencing CAR T-Cell Therapy Market Demand?
• What is the Regulatory Impact on Global Sales of CAR T-Cell Therapy Market?
• Which Region Offers the Largest Opportunity for Sales of CAR T-Cell Therapy Market?
• Where Does the U.S. Stand in the Market for CAR T-Cell Therapy Market?
• What Is the Outlook for CAR T-Cell Therapy Market Manufacturers in China?
• Why is Germany a Lucrative Market for CAR T-Cell Therapy Market Manufacturers?
• Why Will Belgium Outpace Other European Markets for CAR T-Cell Therapy Market?
• Why is There High Demand for Tires in CAR T-Cell Therapy Market?
• Why are Sales of CAR T-Cell Therapy Market Surging?

Contact Us:
Persistence Market Research
305 Broadway,7th Floor New York City, NY 10007 United States
Call +1-646-568-7751
Call +1 800-961-0353
Email Id - sales@persistencemarketresearch.com

About Us -
Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.

This release was published on openPR.